453 results on '"Takimoto, Chris"'
Search Results
2. Contributors
3. P-047 Trial in progress: an open-label, multicenter, phase 1 study for IGM-2644 in participants with relapsed and/or refractory multiple myeloma (RRMM)
4. MDS-482 Impact Of Magrolimab in Combination With Azacitidine on Red Blood Cells (RBCs) in Patients With Higher-Risk Myelodysplastic Syndromes (HR MDS)
5. Two phase I, pharmacokinetic, and pharmacodynamic studies of DFP-10917, a novel nucleoside analog with 14-day and 7-day continuous infusion schedules
6. Supplementary Table 2 from Using Pharmacokinetic and Pharmacodynamic Data in Early Decision Making Regarding Drug Development: A Phase I Clinical Trial Evaluating Tyrosine Kinase Inhibitor, AEE788
7. Supplementary Table 3 from Using Pharmacokinetic and Pharmacodynamic Data in Early Decision Making Regarding Drug Development: A Phase I Clinical Trial Evaluating Tyrosine Kinase Inhibitor, AEE788
8. Editorial on this Article from A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies
9. Supplementary Table 1 from A Phase 1, Dose-Escalation, Pharmacokinetic and Pharmacodynamic Study of BIIB021 Administered Orally in Patients with Advanced Solid Tumors
10. Supplementary Figure 1 from Using Pharmacokinetic and Pharmacodynamic Data in Early Decision Making Regarding Drug Development: A Phase I Clinical Trial Evaluating Tyrosine Kinase Inhibitor, AEE788
11. Supplementary Figure Legends from A Phase 1, Dose-Escalation, Pharmacokinetic and Pharmacodynamic Study of BIIB021 Administered Orally in Patients with Advanced Solid Tumors
12. Supplementary Figures 1-3 from A Phase 1, Dose-Escalation, Pharmacokinetic and Pharmacodynamic Study of BIIB021 Administered Orally in Patients with Advanced Solid Tumors
13. Supplementary Table 2 from A Phase 1, Dose-Escalation, Pharmacokinetic and Pharmacodynamic Study of BIIB021 Administered Orally in Patients with Advanced Solid Tumors
14. Supplementary Table 4 from Using Pharmacokinetic and Pharmacodynamic Data in Early Decision Making Regarding Drug Development: A Phase I Clinical Trial Evaluating Tyrosine Kinase Inhibitor, AEE788
15. Supplementary Table 1 from Using Pharmacokinetic and Pharmacodynamic Data in Early Decision Making Regarding Drug Development: A Phase I Clinical Trial Evaluating Tyrosine Kinase Inhibitor, AEE788
16. Supplementary Figures 1-3, Table 1 from Dietary Genistein Inhibits Metastasis of Human Prostate Cancer in Mice
17. List of Contributors
18. Changing Landscape of Early Phase Clinical Trials
19. Pharmacodynamics and Biomarker Correlates of Imvotamab (IGM-2323), the First-in-Class CD20xCD3 Bispecific IgM Antibody with Dual Mechanisms of Action, in Patients with Advanced B Cell Malignancies
20. Clinical Trials in Special Populations
21. Poster: MDS-482 Impact Of Magrolimab in Combination With Azacitidine on Red Blood Cells (RBCs) in Patients With Higher-Risk Myelodysplastic Syndromes (HR MDS)
22. Microtubule Stabilizing Agents in Clinical Oncology : The Taxanes
23. Novel Targets for the Treatment of Pancreatic Cancer II: The Hedgehog Signaling Pathway
24. Novel Targets for the Treatment of Pancreatic Cancer I: Insulin-like Growth Factor Receptor
25. Novel Agents and New Paradigms for Colorectal Cancer Beyond EGFR and VEGF : Beyond EGFR and VEGF
26. Clinical Experience With 9-Aminocamptothecin : Lessons for New Drug Development
27. Impact of magrolimab treatment in combination with azacitidine on red blood cells in patients with higher-risk myelodysplastic syndrome (HR-MDS).
28. Basic Pharmacokinetics and Pharmacodynamic Principles
29. Population pharmacokinetic analysis of oxaliplatin in adults and children identifies important covariates for dosing
30. Chapter 30 - Nonclinical drug development
31. Poster: AML-196: The First-in-Class Anti-CD47 Antibody Magrolimab in Combination with Azacitidine Is Well Tolerated and Effective in AML Patients: Phase 1b Results
32. AML-196: The First-in-Class Anti-CD47 Antibody Magrolimab in Combination with Azacitidine Is Well Tolerated and Effective in AML Patients: Phase 1b Results
33. Identification of an RNA Binding Site for Human Thymidylate Synthase
34. Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer
35. Metabolism of patupilone in patients with advanced solid tumor malignancies
36. A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC)
37. The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer
38. Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study
39. Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumors
40. A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairment
41. Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies
42. Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies
43. Maximum tolerated dose: clinical endpoint for a bygone era?
44. Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors
45. Phase 0 clinical trials in oncology: a paradigm shift for early drug development?
46. Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study
47. Safety and anti-tumor activity of sorafenib (Nexavar®) in combination with other anti-cancer agents: a review of clinical trials
48. A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma
49. A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer
50. A phase I and pharmacokinetic study of the nonpolyglutamatable thymidylate synthase inhibitor ZD9331 plus docetaxel in patients with advanced solid malignancies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.